Skip to content

Pacific Biosciences of California

US · PACB #3373 by market cap
2.72 +0.02 +0.74%
Live - 5344 symbols - heartbeat 527s ago · 2026-10-08 09:10
Pre-market 2.65 -2.57%
After-hours 2.70 -0.74%
Overnight 2.72 0.00%
Market cap
845.46M
P/B
-25.42
EPS
-1.82
Reader sentiment Are you bullish or bearish on PACB?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    TR | OpenAI - 4o Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $1.5
    Market Newswire · 2025/8/24
  • Rating change
    Morgan Stanley Initiates Pacific Biosciences of California(PACB.US) With Hold Rating, Announces Target Price $2
    Market Newswire · 2025/8/11
  • Piper Sandler Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $2
    Market Newswire · 2026/8/6
  • Rating change
    A Quick Look at Today's Ratings for Pacific Biosciences of California(PACB.US), With a Forecast Between $2 to $3
    Market Newswire · 2025/5/10
  • TD Cowen Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Maintains Target Price $3
    Market Newswire · 2026/8/6
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Biodesix (BDSX), Pacific Biosciences (PACB) and Odyssey Therapeutics, Inc. (ODTX)
    TipRanks · 2026/8/6
  • Rating change
    Analysts Are Bullish on Top Healthcare Stocks: Pacific Biosciences (PACB), 20/20 Biolabs, Inc. (AIDX)
    TipRanks · 2026/5/9
  • CCORF Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Maintains Target Price $3
    Market Newswire · 2026/8/17
  • CCORF Maintains Pacific Biosciences of California(PACB.US) With Buy Rating
    Market Newswire · 2026/9/11
  • Rating change
    Stephens Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Cuts Target Price to $2
    Market Newswire · 2025/11/10
  • Rating change
    Piper Sandler Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Raises Target Price to $2
    Market Newswire · 2025/11/11
  • Rating change
    Barclays Maintains Pacific Biosciences of California(PACB.US) With Sell Rating, Cuts Target Price to $1
    Market Newswire · 2026/4/14
  • Rating change
    Bernstein Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Raises Target Price to $1.7
    Market Newswire · 2025/8/8
  • Rating change
    Piper Sandler Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Cuts Target Price to $1.25
    Market Newswire · 2025/5/16
  • Rating change
    Morgan Stanley Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $2
    Market Newswire · 2025/5/28
  • Rating change
    Barclays Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $2
    Market Newswire · 2025/4/10
  • Barclays Maintains Pacific Biosciences of California(PACB.US) With Sell Rating, Maintains Target Price $1.25
    Market Newswire · 2026/10/7
  • Rating change
    Scotiabank Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Maintains Target Price $2
    Market Newswire · 2025/4/11
  • Rating change
    Barclays Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $1.5
    Market Newswire · 2025/10/3
  • Rating change
    Barclays Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Raises Target Price to $2
    Market Newswire · 2026/2/13

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 09:10:31 · For reference only, not investment advice and not tailored to your situation.